Are Gennex Laboratories Ltd latest results good or bad?

Gennex Laboratories Ltd's latest financial results present a mixed picture, highlighting both robust revenue growth and significant operational challenges. For the fiscal year 2025, the company reported a notable net sales increase of 59.30% year-on-year, reaching ₹137.00 crores, up from ₹86.00 crores in the previous year. This growth is supported by a strong five-year compound annual growth rate (CAGR) of 22.71%, indicating a consistent upward trend in sales. However, the operational metrics reveal concerning trends. The net profit for FY25 rose to ₹18.00 crores, reflecting a 38.46% increase year-on-year, but this growth lagged behind the sales expansion. The profit after tax margin contracted to 13.10% from 15.10% in FY24, suggesting deteriorating operational efficiency. Furthermore, the operating margin (excluding other income) saw a significant decline, dropping to 11.70% from 19.80%, raising questions about the sustainability of the company's profit margins amid rising costs. In the most recent quarter ending December 2025, Gennex reported a net sales growth of 7.37% compared to a much higher growth of 87.05% in the same quarter of the previous year. Similarly, the consolidated net profit growth for this quarter was 12.93%, down from 79.15% year-on-year, indicating a slowdown in profitability momentum. The company's balance sheet shows an increase in shareholder funds to ₹186.69 crores, driven by retained earnings, but also highlights growing working capital pressures. Current liabilities rose, and cash flow from operations turned negative at -₹10.00 crores, suggesting challenges in cash generation despite reported profits. Overall, Gennex Laboratories Ltd's financial results indicate strong revenue growth but are overshadowed by significant margin compression and cash flow concerns. The company has experienced an adjustment in its evaluation, reflecting these operational challenges. Investors should closely monitor the company's ability to stabilize margins and improve cash flow in the coming periods.